Paradoxical effects of statins on aortic valve myofibroblasts and osteoblasts: Implications for end-stage valvular heart disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 3, 2005, Pages 592-597

  Wu, Bing ^a   Elmariah, Sammy ^a   Kaplan, Frederick S ^a   Cheng, Guanjun ^a   Mohler III, Emile R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Aortic valve; Calcification; HMG CoA reductase; Myofibroblasts; Protein prenylation

Indexed keywords

ALKALINE PHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MANUMYCIN; MEVALONIC ACID; PRAVASTATIN; SIMVASTATIN;

ANIMAL CELL; AORTA VALVE; ARTICLE; CALCIFICATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; EVALUATION; LIPID METABOLISM; NONHUMAN; OSTEOBLAST; PRENYLATION; PRIORITY JOURNAL;

ANIMALS; AORTIC VALVE; CALCINOSIS; CELL DIFFERENTIATION; CELLS, CULTURED; CHOLESTEROL; FIBROBLASTS; HEART VALVE DISEASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEVALONIC ACID; OSTEOBLASTS; PRAVASTATIN; PROTEIN ISOPRENYLATION; SIMVASTATIN; STROMAL CELLS; SWINE;

EID: 14644435807     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000154278.01871.64     Document Type: Article

References (30)

1. Mohler ER III. Are atherosclerotic processes involved in aortic-valve calcification? Lancet. 2000;356:524-525.
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999; 340:115-126.
3. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of 'degenerative' valvular aortic stenosis: histological and immunohistochemical studies. Circulation. 1994;90: 844-853.
4. Mohler ER, Gannon FH, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. Circulation. 2001;103:1522-1528.
5. Parhami F, Morrow AD, Balucan J, Leitinger N, Watson AD, Tintut Y, Berliner JA, Demer LL. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation: a possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol. 1997;17:680-687.
6. Proudfoot D, Davies JD, Skepper JN, Weissberg PL, Shanahan CM. Acetylated low-density lipoprotein stimulates human vascular smooth muscle cell calcification by promoting osteoblastic differentiation and inhibiting phagocytosis. Circulation. 2002;106:3044-3050.
7. Parhami F, Basseri B, Hwang J, Tintut Y, Demer LL. High-density lipoprotein regulates calcification of vascular cells. Circ Res. 2002;91: 570-576.
8. Mohler ER, Chawla MK, Chang AW, Vyavahare N, Levy RJ, Graham L, Cannon FH. Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis. 1999;8: 254-260.
9. Watson KE, Bostrom K, Ravindranath R, Lam T, Norton B, Demer LL. TGF-β1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest. 1994;93:2106-2113.
10. Jian B, Narula N, Li QY, Mohler ER III, Levy RJ. Progression of aortic valve stenosis: TGF-ā1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg. 2003;75:457-465.
11. Liao JK. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol. 2002;86:5-18.
12. Callister TQ, Raggi P, Cooli B, Lippolis NJ, Russo DJ. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. N Engl J Med. 1998;339: 1972-1978.
13. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation. 2001;104:2205-2209.
14. Shavelle DM, Takasu J, Budoff MJ, Mao S, Zhao XQ, O'Brien KD. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet. 2002;359:1125-1126.
15. Pohle K, Maffert R, Ropers D, Moshage W, Stilianakis N, Daniel WG, Achenbach S. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation. 2001;104:1927-1932.
16. Mundy G, Garret R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999;286:1946-1949.
17. Garrett IR, Mundy GR. The role of statins as potential targets for bone formation. Arthritis Res. 2002;4:237-240.
18. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA. 2000;283: 3205-3210.
19. Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA. 2000;283: 3211-3216.
20. Chan KA, Andrade SE, Boles M, Buist DS. Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet. 2000;355:2185-2188.
21. Cummings SR, Bauer DC. Do statins prevent both cardiovascular disease and fracture? JAMA. 2000;283:3255-3257.
22. van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA. 2001;285:1850-1855.
23. Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol. 2002;22:1452-1458.
24. Maeda T, Kawane T, Horiuchi N. Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. Endocrinology. 2003;144:681-692.
25. Izumo N, Fujita T, Nakamuta H, Koida M. Lipophilic statins can be osteogenic by promoting osteoblastic calcification in a Cbfa1- and BMP-2-independent manner. Methods Find Exp Clin Pharmacol. 2001;23: 389-394.
26. Rajamannan NM, Subramaniam M, Springett M, Sebo TC, Niekrasz M, McConnell JP, Singh RJ, Stone NJ, Bonow RO, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation. 2002;105: 2660-2665.
27. Demer LL. Cholesterol in vascular and valvular calcification. Circulation. 2001;104:1881-1883.
28. Song C, Guo Z, Ma Q, Chen Z, Liu Z, Jia H, Dang G. Simvastatin induces osteoblastic differentiation and inhibits adipocytic differentiation in mouse bone marrow stromal cells. Biochem Biophys Res Commun. 2003; 308:458-462.
29. Maeda T, Matsunuma A, Kawane T, Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun. 2001;280:874-877.
30. Parhami F, Mody N, Gharavi N, Ballard AJ, Tintut Y, Demer LL. Role of the cholesterol biosynthetic pathway in osteoblastic differentiation of marrow stromal cells. J Bone Miner Res. 2002;17:1997-2003.